RU2016137258A - Композиции вакцин и способы их применения - Google Patents

Композиции вакцин и способы их применения Download PDF

Info

Publication number
RU2016137258A
RU2016137258A RU2016137258A RU2016137258A RU2016137258A RU 2016137258 A RU2016137258 A RU 2016137258A RU 2016137258 A RU2016137258 A RU 2016137258A RU 2016137258 A RU2016137258 A RU 2016137258A RU 2016137258 A RU2016137258 A RU 2016137258A
Authority
RU
Russia
Prior art keywords
ways
application
vaccine compositions
padre
therapeutic agent
Prior art date
Application number
RU2016137258A
Other languages
English (en)
Russian (ru)
Other versions
RU2016137258A3 (enExample
Inventor
Пируз Мохаммад ДАФТАРИАН
Паоло СЕРАФИНИ
Вэнс Пол ЛЕММОН
Вэй Ли
Эйнджел КЕЙФЕР
Бонни Бет БЛОМБЕРГ
Виктор Л. ПЕРЕС
Original Assignee
Юниверсити Оф Майами
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Майами filed Critical Юниверсити Оф Майами
Publication of RU2016137258A publication Critical patent/RU2016137258A/ru
Publication of RU2016137258A3 publication Critical patent/RU2016137258A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016137258A 2009-04-01 2010-04-01 Композиции вакцин и способы их применения RU2016137258A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16573209P 2009-04-01 2009-04-01
US61/165,732 2009-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011144089/15A Division RU2600798C2 (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Publications (2)

Publication Number Publication Date
RU2016137258A true RU2016137258A (ru) 2018-12-13
RU2016137258A3 RU2016137258A3 (enExample) 2020-02-19

Family

ID=42828943

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016137258A RU2016137258A (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения
RU2011144089/15A RU2600798C2 (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011144089/15A RU2600798C2 (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Country Status (9)

Country Link
US (2) US9764012B2 (enExample)
EP (1) EP2413964B1 (enExample)
JP (4) JP5661735B2 (enExample)
CN (2) CN107050440B (enExample)
AU (1) AU2010232512B2 (enExample)
BR (1) BRPI1016133A2 (enExample)
CA (1) CA2756996C (enExample)
RU (2) RU2016137258A (enExample)
WO (1) WO2010115046A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
CA2756996C (en) 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof
WO2010135394A1 (en) * 2009-05-19 2010-11-25 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
KR20140084020A (ko) * 2011-09-07 2014-07-04 미다테크 리미티드 나노입자 종양 백신
WO2013034726A1 (en) * 2011-09-07 2013-03-14 Midatech Limited Nanoparticle-peptide compositions
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
CA2840978A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
KR20140100415A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
WO2014168724A1 (en) * 2013-03-15 2014-10-16 University Of Miami Immune-potentiating drug nanocarriers
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
ES2891081T3 (es) * 2013-08-27 2022-01-26 Deutsches Krebsforsch Modificadores de la respuesta de células T citotóxicas
CN105792842B (zh) * 2013-10-11 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 埃巴病毒疫苗
WO2015116568A2 (en) * 2014-01-28 2015-08-06 University Of Miami Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
CA2999916C (en) * 2015-09-23 2021-07-20 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
US20190184013A1 (en) * 2016-05-23 2019-06-20 University Of Miami Compositions for selective humoral responses and methods of use thereof
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
US10988754B2 (en) * 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
ES3021410T3 (en) 2018-01-28 2025-05-26 Enable Biosciences Inc Reagents and methods for blocking non-specific interactions with nucleic acids
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN110448695B (zh) * 2019-08-23 2021-07-27 中山大学肿瘤防治中心 一种mRNA疫苗递送载体及其制备方法
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023A (en) * 1843-03-30 peters
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US20050169900A1 (en) 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
US6864060B1 (en) * 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
CA2184132C (en) 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
EP0969873B1 (en) 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
AU9031798A (en) * 1997-08-22 1999-03-16 Richard C. Morlock Sensor housing for uv curing chamber
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US6632435B1 (en) 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
EP1473564A4 (en) 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
KR20050044857A (ko) 2001-11-16 2005-05-13 파멕사 에이/에스 무차별 ｔ 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003208314A1 (en) 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20080268457A1 (en) 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
CN1809379A (zh) 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
CN101506266A (zh) 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US7358231B1 (en) 2005-12-01 2008-04-15 Applera Corporation Pancreatic cancer secreted targets and uses thereof
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
US8954355B2 (en) * 2006-01-26 2015-02-10 Psi Systems, Inc. Integrated postage and shipping label system
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5700934B2 (ja) 2007-03-16 2015-04-15 セルスティス リミテッド 細胞性免疫反応アッセイおよびそのためのキット
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
MX2010001194A (es) * 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
CA2756996C (en) 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2756996C (en) 2018-12-11
AU2010232512A2 (en) 2011-10-27
JP2015096520A (ja) 2015-05-21
BRPI1016133A2 (pt) 2016-04-19
CA2756996A1 (en) 2010-10-07
US20180099032A1 (en) 2018-04-12
US20120093761A1 (en) 2012-04-19
WO2010115046A2 (en) 2010-10-07
EP2413964A4 (en) 2013-12-25
JP6139000B2 (ja) 2017-05-31
JP2016188222A (ja) 2016-11-04
CN107050440A (zh) 2017-08-18
RU2016137258A3 (enExample) 2020-02-19
AU2010232512B2 (en) 2013-07-18
RU2011144089A (ru) 2013-05-10
US9764012B2 (en) 2017-09-19
EP2413964A2 (en) 2012-02-08
AU2010232512A1 (en) 2011-10-27
CN102448491A (zh) 2012-05-09
JP2012522802A (ja) 2012-09-27
JP6321261B2 (ja) 2018-05-09
JP5661735B2 (ja) 2015-01-28
EP2413964B1 (en) 2019-11-13
CN107050440B (zh) 2021-10-29
RU2600798C2 (ru) 2016-10-27
JP2017165755A (ja) 2017-09-21
WO2010115046A3 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
RU2016137258A (ru) Композиции вакцин и способы их применения
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
EP3725328A3 (en) Novel adjuvant compositions
RU2016124871A (ru) Композиции бендамустина и циклополисахарида
EP2214705A4 (en) EFFECTIVE VACCINE COMPOSITION WITH A LIPOPEPTIDE AND POLY-I: C AS AN ACTIVE SUBSTANCE
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
BRPI1014854A2 (pt) "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP4374878A3 (en) Pharmaceutical composition
HK1203353A1 (en) Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
EA201100268A1 (ru) Вакцина
EA201290892A1 (ru) Твердые композиции
JP2012522802A5 (enExample)
WO2012170889A8 (en) Cleavable lipids
EA201290506A1 (ru) Частицы для доставки множества агентов
BR112012011268A2 (pt) anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
EP2268320A4 (en) IMAGING THERAPY OF MYOKARD DISEASE: COMPOSITION, MANUFACTURE AND APPLICATIONS
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
EP2314274A3 (en) Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
IN2015DN01092A (enExample)
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
AR068817A1 (es) Cocristales y composiciones farmaceuticas que los componen

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20210923